Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma by Zhiying Fu et al.
Fu et al. Cancer Cell International 2014, 14:5
http://www.cancerci.com/content/14/1/5PRIMARY RESEARCH Open AccessSafety and efficacy of bevacizumab combined
with R-CHOP regimen in seven Chinese patients
with untreated diffuse large B-cell lymphoma
Zhiying Fu, Jun Zhu, Wen Zheng, Weiping Liu, Zhitao Ying, Yan Xie, Xiaopei Wang, Ningjing Lin, Meifeng Tu,
Lingyan Ping, Lijuan Deng, Chen Zhang, Ning Ding and Yuqin Song*Abstract
Background: Rituximab plus CHOP (R-CHOP) significantly improved the outcome of diffuse large B cell lymphoma
(DLBCL), a common sub-type of non-Hodgkin lymphoma. But 40% – 50% of DLBCL patients cannot be cured by
this regimen. Some clinical trials showed that bevacizumab might be useful in the treatment of DLBCL. This study
evaluated the safety and efficacy of bevacizumab combined with the R-CHOP (A-R-CHOP) regimen in Chinese pa-
tients with previously untreated DLBCL.
Methods: Patients with previously untreated DLBCL received A-R-CHOP regimen therapy. All patients with
complete response (CR)/ unconfirmed complete response(CRu) after 8 cycles of A-R-CHOP received the bevacizu-
mab maintenance therapy once every 3 weeks. The remained bulky disease was treated with radiotherapy.
Results: Seven Chinese patients were treated. All of them had bulky diseases. One patient had progressive disease
after 4 cycles of A-R-CHOP therapy. The rest six patients completed 8 cycles of A-R-CHOP treatment. All of these six
patients reached CR/CRu (5 CR, 1 CRu). Bevacizumab maintenance therapy was given to 4 CR patients. All 7 patients
experienced Grade 3/4 hematologic adverse events; additionally, one had Grade 3 gastrointestinal toxicity and one
had Grade 1 epistaxis. During bevacizumab maintenance therapy, one patient had Grade 1 gingival bleeding, an-
other experienced Grade 1 proteinuria and then Grade 3 congestive heart failure 4 months after completion of
maintenance therapy. At the end of July 2013, the patient who had progressive disease after 4 cycles of A-R-CHOP
died of progressive disease, the other six remained CR response.
Conclusions: The A-R-CHOP regimen is effective for untreated DLBCL, but may cause bevacizumab-specific toxic-
ities, which should be monitored.
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According to statistics data in 2008, non-Hodgkin’s
lymphoma (NHL) is the 10th most common tumor
worldwide, with about 300,000 new cases each year [1].
Diffuse large B cell lymphoma (DLBCL) is one of the
most frequently diagnosed sub-types of NHL, which
accounts for about 30% – 50% of all NHL [2,3]. Al-
though several global trials (e.g. GELA LNH98.5 [4],
RICOVER-60 [5], MInT [6]) have demonstrated the* Correspondence: songyuqin622@sina.com
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reproduction in any medium, provided the orefficacy and safety of rituximab combined with chemo-
therapy as the standard treatment for DLBCL, 40% –
50% of DLBCL patients cannot be cured by the standard
R-CHOP regimen(rituximab, cyclophosphamide, doxo-
rubicin, vincristine and prednisone) [2,3].
The role of the vascular endothelial growth factor
(VEGF) in the proliferation of lymphatic malignancies
has been tested in several pre-clinical studies [7,8].
VEGF expressed in neoplastic cells of aggressive lymph-
omas, including DLBCL, mantle cell lymphoma (MCL)
and peripheral T-cell lymphoma (PTCL) as well as in in-
dolent lymphomas such as chronic lymphocytic leukemia/
small lymphocytic lymphoma [9]. These data suggestedThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The A-R-CHOP regimen*
Drug Dose Mode
Bevacizumab† 15 mg/kg i.v. D1
Rituximab‡ 375 mg/m2 i.v. D1
Cyclophosphamide 750 mg/m2 i.v. D1
Doxorubicin 50 mg/m2 i.v. D1
Vincristine 1.4 mg/m2 (≤2 mg) i.v. D1
Prednisone 100 mg/d p.o. D1-5
*1 cycle per 21 days †bevacizumab was given prior to rituximab, the infusion
time of bevacizumab is one hour. ‡the infusion time of rituximab is five hours.
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DLBCL.
Bevacizumab, a 93% humanized IgG1 anti-VEGF
monoclonal antibody, has been tested both as a single
agent (SWOG 0108 study) [10,11] and in combination
with chemotherapy (SWOG0515 study) [12] in DLBCL
patients. The preliminary data showed that bevacizumab
was generally well tolerated and effective in DLBCL. But
they were just single-arm phase II trials. Particularly, no
phase II studies ever included any Chinese patient.
Based on the preliminary results of the above two
phase II studies, a multi-center, randomized, double-
blind, placebo-controlled phase III trial (BO20603) was
initiated in 2009 to compare the safety and efficacy of
bevacizumab plus rituximab and CHOP (A-R-CHOP)
versus R-CHOP in previously untreated CD20+ DLBCL.
Patients were randomized 1:1 to receive A-R-CHOP or
R-CHOP treatments. Our cancer center was the top
recruiting site in China. In total ten patients were en-
rolled into this trial at our center—7 in the A-R-CHOP
arm and 3 in the R-CHOP arm. This paper reported our
own experiences of these 7 Chinese patients who were
treated with bevacizumab plus R-CHOP.
Methods
Patients
The study was approved by the Ethical Committee of the
Peking University Cancer Hospital. The main inclusion cri-
teria were: histologically confirmed DLBCL, left ventricular
ejection fraction (LVEF) ≥ 50%, absolute neutrophils count
(ANC) ≥ 1,500/μL, platelet count ≥ 100,000/μL, adequate
hepatic function (total bilirubin < 1.5 × upper limit of
normal [ULN], both AST and ALT < 2.5 × ULN), ad-
equate renal function (serum creatinine < 2 mg/dL or
177 μmol/L), and urine dipstick test for proteinuria < 2+.
The main exclusion criteria were: CNS involvement,
major blood vessel invasion per CT-scan, and clinical,
radiological, or endoscopic evidence of lymphoma infiltra-
tion of the gastrointestinal tract.
Pathological diagnosis
The DLBCL were classified according to the 4th Edition
of World Health Organization (WHO) Classification of
Tumours of Haematopoietic and Lymphoid Tissues [13].
The diagnoses were confirmed with both morphology
and immunohistochemistry (IHC).The IHC tests in-
cluded those for leucocyte antigen, CD45RO (UCHL1),
CD3, CD5, CD7, CD20 (L26), CD10, BCL6, MUM1,
CD79, CD19, CD30, CD15, CD68 and EMA.
Laboratory evaluation and tumor staging
The DLBCL was staged according to the Ann Arbor sta-
ging system. The workup included hematology, blood
sedimentation, lactate dehydrogenase, beta 2-microglobulin, C-reaction protein, routine urine, CT scans of
neck, chest cavity, abdominal cavity and pelvic cavity,
ultrasound cardiogram (UCG) and bone marrow smear.
Treatments
Patients received the A-R-CHOP regimen as an induc-
tion therapy. The first tumor response assessment was
taken after 4 cycles of treatment. Patients who reached
CR/CRu or PR at this time continued to receive another
4 cycles of the A-R-CHOP regimen.
The second response assessment was performed after
8 cycles of A-R-CHOP therapy. Patients who achieved
CR/CRu received bevacizumab monotherapy (15 mg/kg,
every 3 weeks) as a maintenance therapy. The interval
between the last dose of bevacizumab in A-R-CHOP in-
duction therapy and the first dose of the maintenance
therapy could not exceed 8 weeks. The details of the A-
R-CHOP regimen were summarized in Table 1.
After the second tumor assessment, patients who had
the bulky disease (longest diameter ≥ 7.5 cm by CT scan,
as defined by protocol) could receive the concomitant
radiation therapy to the bulky lesions during the main-
tenance treatment phase if they obtain CR/CRu.
No premedication was given before bevacizumab. Dexa-
methasone (5 mg i.v.) and promethazine (12.5 mg i.m.)
were used before rituximab to prevent allergic reactions.
Routine prophylactic medications were given before the
each cycle of CHOP chemotherapy. Medications included
hydration, alkalinization, diuresis, and tropisetron before
each cycle. All patients received granulocyte colony stimu-
lating factor as prophylaxis for neutropenia.
Assessment of response and adverse events
Assessment of response was performed according to
NCI-WG 1999 criteria [14].
The safety assessment was performed according to the
National Cancer Institute Common Toxicity Criteria for
Adverse Events (CTCAE) version 3.0 [15].
Follow-up
LVEF was measured at the following time points: base-
line, after 4 and 8 cycles of therapy, and at 1 year post
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quired to come back to the cancer center every 3
months for follow-up visits. Lab tests and examinations
at the follow-up visit include CT scan, hematology,
chemistry, and C-reactive protein, and LVEF in patients
who experienced cardiac toxicities.
Results
Efficacy assessment
From May 2009 to May 2010, seven untreated Chinese
DLBCL patients (6 females and 1 male) were enrolled
into the A-R-CHOP arm of this trial at our center.
Informed consents were obtained from all participants.
The median age at initial diagnosis was 34 years (range:
18–50). All patients had bulky disease. Patient character-
istics are summarized in Table 2.
Seven patients received bevacizumab every 21 days
(15 mg/kg), with R-CHOP on the first day. After 4 cycles
of A-R-CHOP treatment, five patients reached CRu, one
PR, and one progressed.Table 2 Clinical characteristics of 7 patients with diffuse
large B cell lymphoma
Characteristic n (%)
















Bulky disease (longest diameter ≥ 7.5 cm
by CT scan)
Mediastinum 5 (71.4)
Abdominal cavity 2 (28.6)
B symptoms
Weight lose 2 (28.6)
Fever 1 (14.3)
Laboratory abnormalities
LDH (>240 IU/L) 6 (85.7)
C-reactive protein increased 6 (85.7)This progressed female patient withdrew from this
study and then was treated with DICE regimen but failed
again. She died of tumor progression. Her overall sur-
vival time was 8 months.
The other six patients completed all 8 cycles of A-R-
CHOP therapy. The second assessment showed five CR
and one CRu. Among these six patients, two female pa-
tients did not receive the bevacizumab maintenance
treatment. One patient with CR did not receive mainten-
ance treatment because the planned maintenance ther-
apy was delayed by radiotherapy and not started within
8 weeks after the last dose of bevacizumab in A-R-
CHOP. The other one was stopped by the sponsor of
the trial due to the risk-benefit assessment. The median
number of total bevacizumab treatments was 12 times.
The median number of maintenance treatments was 4
times. All six patients were alive and remained in CR
when the follow-up ended on 30 July 2013 (Table 3).
Safety
All seven patients experienced Grade 3/4 hematologic
toxicities. One had Grade 3GI toxicity and Grade 2
thrombocytopenia. Another patient suffered from the
Grade 1 epistaxis. In the maintenance treatment phase,
one patient had transient gum bleeding, another one ex-
perienced Grade 1 proteinuria, and later developed Grade
3 congestive heart failure (CHF) after having completed
the bevacizumab maintenance therapy.
Discussion
Bevacizumab was the first anti-angiogenic drug that was
approved by the U.S. Food and Drug Administration in
2004 and by the European Medicines Agency in 2005.
Several randomized trials have demonstrated that adding
bevacizumab into standard chemotherapies could pro-
long the overall survival in colorectal cancer and
progression-free survival in non-small cell lung cancer,
breast cancer and renal cell carcinoma. However, the
safety concerns of the administration of bevacizumab
have existed for a long time. E.g. a meta-analysis sug-
gested that the bevacizumab was associated with a
higher risk for all grade 3/4 AE [16].
For the treatment of lymphoma, bevacizumab had
been explored for DLBCL, PTCL, MCL and NK/T cell
lymphoma. Study E2404 showed that despite a higher
overall response rate, the A-CHOP regimen failed to re-
sult in durable remissions and was associated with sig-
nificant toxicities [17]. For DLBCL, the final result of the
phase II study S0515 demonstrated that the A-R-CHOP
regimen was not promising in terms of PFS and induced
severe toxicities (81% of all 64 patients had Grade 3 or
higher toxicities, notably the cardiac toxicities and
gastrointestinal perforations) [18]. The phase III study
(BO20602) was also terminated prematurely due to the
Table 3 Treatment outcome of all seven patients






Radiotherapy (Gy) 3rd assessment
1 CRu CR 0 40.6 CR
2 CRu CR 7 40 CR
3 CRu CR 7 36 CR
4 PD NAa 0 No NA
5 CRu CR 6 42 CR
6 CRu CR 4 42 CR
7 PR CRu 0 50 CR
CR: complete remission, CRu: complete remission unconfirmed, PR: partial remission, PD: progressive disease. NA, not assessed. aPatient No. 4 withdrew after the
first assessment.
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pendent Data and Safety Monitoring Board (DSMB) on
30 May 2010. There were several articles discussed the
bevacizumab treatment in NHL before, but none of
them involved Chinese patients. So the safety and effi-
cacy data of bevacizumab in Chinese lymphoma popula-
tion are very limited. Although only a very small
population was reported in this paper, the information
was valuable and could be helpful for lymphoma special-
ists. In the following part of this section, based on the
bevacizumab associated toxicities discovered in this
study at our site, we would go to discuss hemorrhage,
proteinuria and cardiovascular toxicities.
Hemorrhage
VEGF is important to maintain the integrity of the vas-
cular endothelial cells. Antagonist of VEGF could reduce
the endothelial regeneration and may cause bleeding. A
meta-analysis of 12,617 patients who were treated with
bevacizumab demonstrated significantly increased risk of
bleeding (RR: 2.48; 95% CI: 1.93–3.18). The incidence of
all-grade hemorrhage was 30.4% (95% CI 21.5-40.9), with
3.5% (95% CI 2.2-5.7%) being high grade (grade 3-5)
[19]. To reduce the risk of severe hemorrhage in our
study, the protocol excluded patients who have lesions
involving large blood vessels on CT scan. Two patients ex-
perienced Grade 1 mucosal bleeding: epistaxis (7 cycles of
bevacizumab, total dose: 7350 mg), and transient gum
bleeding (10 cycles of bevacizumab, total dose: 8850 mg).
Proteinuria
Proteinuria is associated with bevacizumab treatment
[20]. A meta-analysis of 6482 patients treated with beva-
cizumab showed increased risk of proteinuria (RR: 2.79;
95% CI: 1.31–5.95, P < 0.001) [21]. Eremina et al. per-
formed renal biopsies on six patients of bevacizumab
treatment with proteinuria. The results of these biopsies
indicated the glomerular thrombosis microvascular dis-
ease in the kidney. The animal experiments showed that
bevacizumab could inhibit the protective effect of VEGFon endothelial cell. This inhibition might increase the
glomerular filtration permeability and decrease absorption
capacity heavily. Eventually the proteinuria appeared [22].
In our study, all seven patients received urine dipstick
tests to monitor proteinuria before and during bevacizu-
mab treatment. One patient had asymptomatic protein-
uria (urine protein 2+) after 12 bevacizumab treatments
(total dose: 10,980 mg). The 24-hour urinary protein
quantity in this patient was 248 mg after the proteinuria
was 3+ in the dipstick test. There was not any significant
organic disease found in the kidney ultrasound examin-
ation. This patient was under close observation without
any treatment. His proteinuria recovered 6 months after
its initial diagnosis.
Cardiovascular toxicities
CHF and myocardial ischemia are most severe cardio-
vascular toxicities of bevacizumab. One article reported
the molecular mechanisms of cardiovascular toxicity of
bevacizumab [23]. A number of studies showed that
anthracycline-based drug therapy and/or thoracic radio-
therapy are risk factors of CHF [24]. Vaklavas et al.
reviewed all prospective phase I–III clinical trials pub-
lished about approved bevacizumab therapies and rele-
vant literature up to December 2008, and found Grade
3–4 left ventricular systolic dysfunction was noted in
0.3% of patients [25].
In our study, a 45-year-old female patient experienced
CHF after the following therapies: 8 cycles of A-R-
CHOP treatment and 4 cycles of bevacizumab mainten-
ance therapy with concomitant radiotherapy on the
bulky abdominal lesion. She did not have any prior his-
tory of heart disease. The baseline LVEF was 65%. But it
decreased to 35% 4 months after the last dose of bevaci-
zumab therapy. She was admitted to the hospital to con-
trol the CHF. The CHF alleviated after 4 weeks’
treatment. She was then discharged from the hospital
with oral cardiotonics and diuretics. Three months later,
the LVEF recovered to 69%. The LVEF was 56% and 60%
at six months and one year after her hospital discharge,
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icity in patients who were treated with bevacizumab
might be reversible. This was also reported in another
paper [26].
Conclusion
In this small population, the addition of the bevacizumab
to the standard R-CHOP regimen caused bevacizumab-
specific toxicities. Although the gum bleeding, epistaxis
and proteinuria were mild, the congestive heart failure
was a more severe. Early detection and personalized man-
agement may improve clinical outcome tolerance. This
implies that the cardiac toxicity of the A-R-CHOP regi-
men should be monitored closely.
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